



Dr. Marius König

Assistenzarzt/Assistenzärztin

**Allgemeine Innere Medizin | Hausarztmedizin und Notfallmedizin,
Gastroenterologie | Hepatologie · Dept. I**

Kontakt

Dr. Marius König
Rorschacherstrasse 95
9007 St. Gallen
Switzerland

T +41 71 494 9963
Marius.Koenig@kssg.ch

Bereiche

Allgemeine Innere Medizin | Hausarztmedizin und Notfallmedizin, Gastroenterologie | Hepatologie

Funktion

Assistenzarzt/Assistenzärztin

Publikationen (3)

Woelfel S, Dütschler J, König M, Dulovic A, Graf N, Junker D, Oikonomou V, Krieger-Grübel C, Truniger S, Franke A, Eckhold A, Forsch K, Koller S, Wyss J, Krupka N, Oberholzer M, Frei N, Geissler N, Schaub P, STAR SIGN Study Investigators, Albrich W, Friedrich M, Schneiderhan-Marra N, Misselwitz B, Korte W, Bürgi J, Brand S. STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2023; 58:678-691.

Woelfel S, Dütschler J, König M, Graf N, Oikonomou V, Krieger-Grübel C, Truniger S, Franke A, Eckhold A, Forsch K, Wyss J, Krupka N, Albrich W, Frei N, Geissler N, Schaub P, STAR SIGN Study Investigators, Friedrich M, Misselwitz B, Korte W, Bürgi J, Brand S. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2. *Aliment Pharmacol Ther* 2022; 57:103-116.

Maeder M, König T, Bogdanovic S, Schneider I, Eugster W, Ammann P, König M, Beer J, Rickli H. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland. *Swiss Med Wkly* 2017; 147:w14503.

Projekte (5)

Frequency and Clinical Significance of PR3- and MPO Antineutrophil Cytoplasmic Antibodies (ANCA) in Ulcerative Colitis and Crohn's Disease (IBD-ANCA Study)

Klinische Forschung - 01.07.2023 - 01.07.2025

Laufend

VedolizumAb in IBD - Real-world non-Interventional, ProspEctive, ObservaTional StudY to describe real-world treatment patterns in patients on vedolizumab treatment

Klinische Forschung - 14.07.2022 - 31.12.2023

Automatisch geschlossen

I6T-MC-AMAX

Klinische Forschung - 07.06.2022 - 31.12.2024

Laufend

CED-4/CEL

Klinische Forschung - 01.06.2022 - 31.12.2024

Laufend

Analysis of the effect of biological therapy on SARS-CoV-2-specific antibody levels following booster vaccination in patients with inflammatory bowel disease

Klinische Forschung - 20.01.2022 - 30.03.2023

Automatisch geschlossen